Medroxyprogesterone Acetate (MPA) is a synthetic progestogen and acetate ester of medroxyprogesterone. It is a steroidal pharmaceutical compound that produces effects similar to those of the naturally occurring hormone progesterone.
Medroxyprogesterone Acetate is widely used in pharmaceutical formulations for contraception, gynecological conditions and hormone-related therapies. It is available in oral and injectable dosage forms, with the injectable form being used as a long-acting hormonal contraceptive.
Medroxyprogesterone Acetate has the molecular formula C24H34O4 and a molecular weight of approximately 386.53 g/mol. Its CAS Number is 71-58-9.
It is a synthetic pregnane steroid and is structurally related to progesterone. The acetate ester provides different physicochemical and pharmacokinetic properties compared with medroxyprogesterone itself.
Medroxyprogesterone Acetate acts primarily as an agonist of progesterone receptors. After binding to progesterone receptors, the resulting receptor complex influences the expression of progesterone-responsive genes.
In contraceptive applications, MPA suppresses gonadotropin secretion and ovulation, while also producing changes in cervical mucus and the endometrium that contribute to contraceptive activity.
Medroxyprogesterone Acetate is used in pharmaceutical formulations for:
The approved indications depend on the dosage form, strength and regulatory jurisdiction.
Medroxyprogesterone Acetate API can be evaluated using validated analytical procedures for identification, assay, related substances, water content, residual solvents, elemental impurities and other applicable quality attributes.
HPLC, infrared spectroscopy and other validated analytical methods may be used for identification, assay and purity determination. Steroidal impurities, degradation products and residual process-related impurities should be appropriately controlled.
Final acceptance criteria should be based on the applicable manufacturer's approved drug-substance specification and Certificate of Analysis.
Medroxyprogesterone Acetate should be stored in a tightly closed pharmaceutical-grade container under controlled conditions and protected from excessive heat, moisture and direct light.
Specific storage and transportation conditions should follow the applicable manufacturer's approved specification.
Medroxyprogesterone Acetate API may be supplied for qualified pharmaceutical manufacturing, formulation development, analytical and research applications, subject to applicable regulatory and quality requirements.
Medroxyprogesterone Acetate API is available for qualified pharmaceutical development and manufacturing requirements. Customers can request product specifications, Certificate of Analysis, analytical documentation, packaging information and commercial details according to their requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 1.0% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 2.0% |
| Melting Point | Approximately 200–210 °C |